Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Por um escritor misterioso
Descrição
Rucaparib improves rPFS vs docetaxel or 2nd-generation ARPI in BRCA-mutated mCRPC, Latest news for Doctors, Nurses and Pharmacists
Frontiers Applications for open access normalized synthesis in metastatic prostate cancer trials
ESMO 2018: Preliminary Results From TRITON2: A Phase II Study of Rucaparib in Patients with mCRPC Associated with Homologous Recombination Repair Gene Alterations
Cancers, Free Full-Text
PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?
Rucaparib Gets a Win in Metastatic Castration-Resistant Prostate Cancer
Pathways involved in natural progression of prostate cancer
Advanced Prostate Cancer: AUA/SUO Guideline - American Urological Association
Frontiers Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
de
por adulto (o preço varia de acordo com o tamanho do grupo)
